CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
Capros dietary supplementdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01858376
NCT01858376N/ACompleted
CompareCT.gov

Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans

Chandan K Sen·interventional·Posted May 21, 2013·Updated Jul 27, 2018

In Brief

A clinical study evaluating Capros dietary supplement for Hyperlipidemia. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The hypothesis of this study is that the natural supplement Capros will decrease LDL levels, platelet aggregation, and serum concentrations of high sensitivity C-reactive protein in humans at risk for cardiovascular disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperlipidemia
CountriesUnited States
CollaboratorsNatreon, Inc.

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 21, 2013
Enrollment StartMar 1, 2013
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.1 years ago

Interventions

Capros dietary supplementdietary

Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.